Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 5/20 | 0.47 |
| ▸ | CES1 | P23141 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10946374 | 0.98 | ELANE (0.46) | ELANECES1MAOBATML3MBTL1 | |
| SCHEMBL29281053 | 0.90 | ELANE (0.51) | ELANEMAOBATML3MBTL1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL11498996 | 0.90 | ELANE (0.41) | ELANECES1MAOBATML3MBTL1 | |
| SCHEMBL9543659 | 0.88 | HDAC1 (0.50) | ELANETDP1HDAC1HDAC2KDM4E | |
| SCHEMBL29281054 | 0.86 | POLB (0.49) | CES1ATML3MBTL1TDP1HPGD | |
| SCHEMBL544447 | 0.84 | MAOB (0.49) | ELANECES1MAOBATML3MBTL1 | |
| SCHEMBL4658587 | 0.83 | AKR1C3 (0.51) | MAOBHDAC1HDAC2HSD17B10ALDH1A1 | |
| SCHEMBL25694687 | 0.83 | ELANE (0.42) | ELANECES1MAOBL3MBTL1TDP1 | |
| SCHEMBL31257827 | 0.83 | ELANE (0.44) | ELANECES1MAOBATML3MBTL1 | |
| SCHEMBL21235982 | 0.83 | ELANE (0.53) | ELANEMAOBATML3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 314 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2025-05-08 | — | — | US | claimed |
| CN-119742387-A | Full-temperature-range lithium-manganese dioxide soft-package battery electrolyte and battery obtained by same | 惠州市惠德瑞锂电科技股份有限公司 | 2025-04-01 | — | — | CN | claimed |
| CN-115842112-B | Secondary battery, battery module, battery pack and power utilization device thereof | 宁德时代新能源科技股份有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-118315657-A | Gel electrolyte, preparation method thereof and energy storage device | 深圳市合壹新能技术有限公司 | 2024-07-09 | — | — | CN | claimed |
| CN-113903993-B | Lithium metal battery electrolyte additive, electrolyte and battery thereof | 中国科学院大学 | 2024-04-09 | — | — | CN | claimed |
| CN-115832180-B | Secondary battery, battery module, battery pack and power utilization device thereof | 宁德时代新能源科技股份有限公司 | 2024-03-22 | — | — | CN | claimed |
| WO-2023130888-A1 | SECONDARY BATTERY, BATTERY MODULE, BATTERY PACK AND ELECTRIC DEVICE THEREOF | 宁德时代新能源科技股份有限公司 | 2023-07-13 | — | — | WO | claimed |
| WO-2023130887-A1 | SECONDARY BATTERY, BATTERY MODULE, BATTERY PACK AND ELECTRIC DEVICE THEREOF | 宁德时代新能源科技股份有限公司 | 2023-07-13 | — | — | WO | claimed |
| CN-115842112-A | Secondary battery, battery module, battery pack, and electric device using the same | 宁德时代新能源科技股份有限公司 | 2023-03-24 | — | — | CN | claimed |
| CN-115832180-A | Secondary battery, battery module, battery pack, and electric device using the same | 宁德时代新能源科技股份有限公司 | 2023-03-21 | — | — | CN | claimed |
| EP-2468708-A1 | Catalytic decarboxylative cross-ketonisation of aryl- and alkylcarboxylic acids using iron catalysts | Cognis IP Management GmbH (DE) | 2012-06-27 | — | — | EP | claimed |
| US-7935530-B2 | Selectively bind DNA and entering nucleus of cells; for modulating gene expression in cells | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2011-05-03 | — | — | US | claimed |
| US-20080269138-A1 | Polyamides with tail structures | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2008-10-30 | — | — | US | claimed |
| WO-2008066890-A2 | POLYAMIDES WITH TAIL STRUCTURES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-06-05 | — | — | WO | claimed |
| CN-1856461-A | Cycloalkylene compounds as estrogen receptor modulators | SMITHKLINE BEECHAM CORP (US) | 2006-11-01 | — | — | CN | claimed |
| EP-1521757-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | AstraZeneca AB (SE) | 2005-04-13 | — | — | EP | claimed |
| WO-2004005295-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | claimed |
| WO-2001014083-A1 | AMINE CURABLE FOUNDRY BINDER CONTAINING AN ESTER OF CERTAIN ORGANIC ACIDS | ASHLAND INC. (US) | 2001-03-01 | — | — | WO | claimed |
| US-4395521-A | Process for curing thermoset resins using phenyl esters of carboxylic acids as latent catalysts | UNION CARBIDE CORPORATION (US) | 1983-07-26 | — | — | US | claimed |
| US-4297485-A | Production of a selectively protected N-acylated derivative of an aminoglycosidic antibiotic | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1981-10-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269138-A1 | Polyamides with tail structures | HNRNPH3, PCNA, DNAH12 | ELANE 1540/4885CES1 2405/4885MAOB 3873/4885 |
| US-20250144226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CLN6, CACYBP, CREBBP | ELANE 2043/4885CES1 1003/4885MAOB 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.